...
首页> 外文期刊>Journal of the International Aids Society >Implementation of pre‐exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy
【24h】

Implementation of pre‐exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy

机译:人体免疫缺陷病毒感染的暴露前预防的实施:研究和政策方面的进展和新出现的问题

获取原文
           

摘要

Background In this article, we present recent evidence from studies focused on the implementation, effectiveness and cost‐effectiveness of pre‐exposure prophylaxis (PrEP) for HIV infection; discuss PrEP scale‐up to date, including the observed levels of access and policy development; and elaborate on key emerging policy and research issues to consider for further scale‐up, with a special focus on lower‐middle income countries. Discussion The 2015 WHO Early Release Guidelines for HIV Treatment and Prevention reflect both scientific evidence and new policy perspectives. Those guidelines present a timely challenge to health systems for the scaling up of not only treatment for every person living with HIV infection but also the offer of PrEP to those at substantial risk. Delivery and uptake of both universal antiretroviral therapy (ART) and PrEP will require nation‐wide commitment and could reinvigorate health systems to develop more comprehensive “combination prevention” programmes and support wider testing linked to both treatments and other prevention options for populations at highest risk who are currently not accessing services. Various gaps in current health systems will need to be addressed to achieve strategic scale‐up of PrEP, including developing prioritization strategies, strengthening drug regulations, determining cost and funding sources, training health providers, supporting user adherence and creating demand. Conclusions The initial steps in the scale‐up of PrEP globally suggest feasibility, acceptability and likely impact. However, to prevent setbacks in less well‐resourced settings, countries will need to anticipate and address challenges such as operational and health systems barriers, drug cost and regulatory policies, health providers’ openness to prescribing PrEP to populations at substantial risk, demand and legal and human rights issues. Emerging problems will require creative solutions and will continue to illustrate the complexity of PrEP implementation.
机译:背景技术在本文中,我们提供了来自研究的最新证据,这些研究集中于HIV感染前接触预防(PrEP)的实施,有效性和成本效益。讨论迄今为止的PrEP扩大,包括观察到的访问和政策制定水平;并详细阐述了主要的新兴政策和研究问题,以考虑进一步扩大规模,特别是针对中低收入国家。讨论《 2015年世界卫生组织关于艾滋病毒的治疗和预防的早期发布指南》反映了科学证据和新的政策观点。这些指南对卫生系统提出了及时的挑战,不仅要扩大对每个感染艾滋病毒的人的治疗,而且还要向有严重风险的人提供PrEP。通用抗逆转录病毒疗法(ART)和PrEP的交付和采用都需要全国范围的承诺,并且可以重振卫生系统,以开发更全面的“联合预防”计划,并支持针对高风险人群的与治疗和其他预防方案相关的更广泛的测试目前没有访问服务的人。为了实现PrEP的战略扩大,将需要解决当前卫生系统中的各种差距,包括制定优先级战略,加强药物法规,确定成本和资金来源,培训卫生服务提供者,支持用户依从性和创造需求。结论在全球范围内扩大PrEP的初始步骤表明可行性,可接受性和可能的​​影响。但是,为防止资源贫乏的地区遭受挫折,各国将需要预见并应对各种挑战,例如运营和卫生系统壁垒,药品成本和监管政策,卫生服务提供者对面临重大风险,需求和法律的人群开具PrEP的开放性和人权问题。新兴问题将需要创造性的解决方案,并将继续说明PrEP实施的复杂性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号